Similarly, Yu et al.16 treated 29 patients with advanced NSCLC who slowly progressed after first-generation EGFR-TKI monotherapy with the combination of original drug and Apatinib, and showed that the ORR, DCR, and mPFS of patients significantly improved, while the rate and the severity of the adverse reactions was acceptable and controllable. This evidence concerns the gene EGFR and non-small cell lung carcinoma.